While NRAS and/or KRAS mutations were reported as having a neutral impact on survival in AML [45, 46], a recent study on a large cohort of intensively-treated AML patients over 60 showed that NRAS or KRAS mutations had an independent negative impact on survival [47]. This evidence concerns the gene NRAS and acute myeloid leukemia.